publication date: Mar. 14, 2014
NCI Rethinks Cancer Center Grants
NCI is moving toward adopting a formula that will fundamentally restructure the manner in which cancer centers are funded.
The new approach, developed by a working group of the National Cancer Advisory Board, seeks to eliminate the advantage that comes with a center’s longevity in the program.
As it stands, just being in the centers program for many cycles can build up an institution’s funding base. This favors older centers.
|Robert Cook-Deegan’s Viewers’ Guide To the Super Bowl of Gene Patent Cases|
Patent litigation is a blood sport if you see corporations as people and count spilled ink or loss of money as hemorrhage.
One of the most closely watched cases in recent years centers on genetic testing for BRCA1 and BRCA2 genes.
On March 10, Judge Robert Shelby from the Federal District Court for Utah denied Myriad Genetics’ motion for a preliminary injunction against its competitors that had entered the market starting June 13, 2013, when the Supreme Court handed down its ruling in Association of Molecular Pathology v. Myriad Genetics.